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Sex & Gender: The Politics, Policy, and Practice of
Medical Research
Sarah K Keitt, M.P.H.*
While women generally live longer than men,' they often do not live
healthier.! Historically, women have suffered from a lack of medical
information specific to their needs and problems.3 This information gap is
the result of policies and practices that excluded women from
participating as research subjects in most clinical trials until the late 1980s.
Women were initially excluded from participating in clinical trials due to
neglect and, after the Thalidomide tragedy of the 1960s, misguided efforts
at protection. It was not until the mid-1980s that the medical research
community began to recognize that the information gap created by these
policies had a detrimental effect on women's health and began to take
action to fill this gap.
This Article explores issues surrounding women's participation in
clinical trials. Part I outlines the cultural and regulatory norms that for
many years resulted in the exclusion of women from clinical trials. It
includes a discussion of protectionist regulations, landmark legislation,
and the backlash against the women's health movement. Part II provides
* Sarah K. Keitt is a program manager with the Society for Women's Health Research. She
would like to acknowledge and thank Dr. Florence P. Haseltine for her substantial
contributions to this Article. Dr. Haseltine is currently the Director of the Center for
Population Research at the National Institute of Child Health and Human Development
and is the founder of the Society for Women's Health Research.
1. Robert N. Anderson, United States Life Tables, 1997, NAT'LVITAL STAT. REP., Dec. 13,
1999, at 1, 3.
2. BERNADINE HEALY, A NEW PRESCRIPTION FOR WOMEN'S HEALTH 16 (1995); Terie T.
Wetle & RichardJ. Havlik, Foreword to THE WAOMEN'S HEALTH AND AGING STUDY: HEALTH AND
SOCIAL CHARACTERISTICS OF OLDER WOMEN WITH DIsABIrITy, at xii (Jack M. Guralnik et al.
eds., 1995).
3. U.S. Pub. Health Serv., Report ofthe Public Health Service Task Force on Women's Health
Issues, 100 PuB. HEALTH REP. 73 (1985).
4. See also Edward N. Brandt, Jr., Some Thoughts About Women's Health and Its Evolution, 1
J. GENDER-SPECIFIC MED. 48, 48-49 (1988) (discussing the establishment of a U.S.
Department of Health and Human Services Talk Force to analyze and assess the
information gap).
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recommendations for improving the research process to allow for more
equitable and scientifically sound research on the health issues that affect
women. These recommendations include closer attention to the needs of
female research participants, as well as novel methods of study design and
data analysis.
I. THE HISTORY OF THE WOMEN'S HEALTH MOVEMENT
A. The Traditional Paradigm
Anyone who has taken a course in human biology, physiology, or
pharmacology is familiar with the "Typical 70 Kilogram Man."' Our
knowledge of human biology is based on this archetype as the standard
human research subject. For decades, biologists and medical researchers
approached the study of human biology from the point of view that
whatever happened in the "70 Kilogram Man" was the norm, and that
anything that differed from that norm, including female biology, was
"atypical," or even abnormal. A quick Medline search shows that this
model is still in use; practice guidelines and research examples are often
expressed in terms of the 70 kilogram male.7
Until recent years, most researchers belonged to one of two camps
(and sometimes both): one group saw females as smaller versions of males
and thus viewed the study of women as unnecessary; the other group
believed that women were too complicated to study because their
hormonal cycles made them difficult subjects and led to complicated data.'
Research results from men were routinely incorporated into treatment
guidelines for women, regardless of acknowledged male/female
5. See, e.g., ROBERT L. VICK, CONTEMPORARY MEDICAL PHYSIOLOGY (1984) (using the "70
Kilogram Man" as the standard throughout).
6. See HEALY, supra note 2, at 8.
7. See, e.g., Robert Cartotto et al., Minimizing Blood Loss in Burn Surgery, 49 J. TRAUMA
1034 (2000); Mark V. Dahl & Alina G. Bridges, Intravenous Immune Globulin: Fighting
Antibodis with Antibodies, 45 J. AM. AcAD. DERMArOLOcY 775 (2001); Mark A. Healey et al.,
Irreversible Shock At Not Irreversible: A New Model of Massive Hemorrhage and Resuscitation, 50J.
TRAuMA 826 (2001); Wilbur Huang et al., Pharmacology of Botulinum Toxin, 43J. AM. ACA,.
DERMATOLOGY 249 (2000);Jerry W. Shay & Woodring E. Wright, Aging: 14%en Do Telomeres
Matter?, 291 SCIENCE 839 (2001).
8. Tracy L. Johnson & Elizabeth Fee, Women's Health Research: An Introduction, in
WOMEN'S HFALTH RESEARCHi: A MEDICAL AND POLICY PRIMER 3, 14-15 (Florence P. Haseltine
& Beverly GreenbergJacobsen eds., 1997) [hereinafter WOMEN'S HEALTH RI SEARcH].
111:2 (2003)
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differences in body fat, hormones, and other physiological functions.
Policies aimed at protecting the fetus and women's reproductive
potential added to this preference for male subjects. In 1962, the Kefauver-
Harris Amendment, perhaps the most important piece of legislation
regulating the conduct of clinical trials, was passed with the purpose of
protecting children, pregnant women, and fetuses. The Kefauver-Harris
amendment required drug manufacturers to demonstrate that new drugs
were safe and effective via adequate and well-controlled clinical trials." This
legislation was passed in response to the thousands of babies born with
severely deformed limbs as a result of in utero exposure to Thalidomide.
Later, during the early 1970s, research revealed that the daughters of
women who took diethylstilbestrol (DES) during pregnancy had an
increased risk of vaginal cancer.' In 1977, the United States Food and
Drug Administration (FDA) responded to these two events by issuing
guidelines that required women of childbearing potential to be excluded
from drug trials until teratogenicity data from animal studies of the drug
were available." The only exception to these guidelines was for drugs used
in the treatment of life-threatening or serious diseases. Because
teratogenicity studies were usually performed at the same time as clinical
trials in humans, these guidelines had the effect of excluding women from
most drug trials. 2 When the general acceptance of the male norm was
coupled with images of deformed babies, the medical community did not
question the exclusion.
B. The Women's Health Movement: A Sea Change in Public Policy
Despite their commendable purpose, the 1977 guidelines did more
harm than good. In 1983, then-Assistant Secretary for Health Dr. Edward
Brandt found that while the United States Public Health Service published
a great deal of health information on menstruation, menopause,
9. Drug (Kefauver-Harris) Amendments of 1962, Pub. L. No. 87-781; 76 Stat. 780
(codified as amended in scattered sections of 21 U.S.C.); see also Mark S. Schreiner &
William i. Greeley, Safe and Effective for Children?, 141 AM. HEAR1J. 3, 3-5 (2001).
10. Arthur L. Herbst et al., Adenocarcinoma of the Vagina: Association of Maternal Stilbestrol
Therapy with Tumor Appearance in Young Women, 284 NEw ENG. J. MED. 878 (1971).
11. U.S. DEP'T HEALTH & HUMAN SERvS., FOOD & DRUGADMIN., HEW PUB. No. 77-3040,
GENERAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF DRUGS (1978).
12. Susan Flamm Honig, Ethical Issues in Recruitment: Communicating the Risks to Women of
Childbearing Potential, in THE SOCIETY FOR WOMEN'S HEALTH RESEARCH, PROCEEDINGS FROM
WOMEN AND CLINICAL RESEARCH: BREAKING THROUGH THE BARRIERS TO RECRUITMENT AND
RETENTION 9,9-11 (2001).
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pregnancy, and breast diseases, there was a lack of information on other
conditions, such as heart disease, that affect women. To address this
situation, Dr. Brandt appointed a task force on women's health issues to
develop an analysis of women's health activities and an agenda for further
activities. 3 In 1985, the task force concluded that the lack of a research
focus on women's health issues compromised the quality of health
information available to women as well as the health care they received.
1 4
The report's findings prompted the National Institutes of Health (NIH) to
develop guidelines urging the inclusion of women of child-bearing
potential in federally funded clinical research. 15 Researchers and women's
health advocates soon became aware, however, that the inclusion
guidelines were not enforced and that women were still routinely excluded
from clinical trials.
16
In 1990, researchers and advocates concerned about the inclusion of
women in medical research organized into what later became the Society
for Women's Health Research.'7 At the urging of the Society, Congress
ordered the General Accounting Office (GAO) to conduct a study into
NIH's policies and practices regarding the inclusion of women. The
resulting GAO report disclosed the lack of improvement in tie inclusion
of women in NIH-funded research. Specifically, the report found that the
NIH policy had not been well communicated or understood within NIH or
the research community, was applied inconsistently across institutes, and
only applied to extramural research. ' The GAO also found that despite
their own published recommendations, NIH officials had done little to
encourage the analysis of study data by sex. Finally, the 1990 GAO report
concluded that there was no readily accessible source of data on the
demographics of NIH study populations. 9 The 1990 GAO report signaled a
13. Brandt, supra note 4.
14. See U.S. Public Health Service, supra note 3.
15. 15 NAT'i INST. HKLTH, NIH GuIDE FOR GRA'rSAND CONFRACTS (1986) ("[T]he
NIH urges applicants for grants and offerors for contracts to consider the inclusion of
women in the study populations for all clinical research efforts.... If women are not
included, a clear rationale should be provided for their exclusion.").
16. Problens in Implerumting the National Institutes of Health Policy on Women in Study
Populations: Hearing Before the Subcomm. on Housing and Consumer Interest of the House Select
Comm. on Aging, 101st Cong. (1990) [hereinafter Hearing] (statement of Mark V. Nadel,
Associate Director, U.S. Gen. Accounting Office).
17. The Society br Women's Health Research: About the Society, Society, Histmy, at
http://www.womens-health.org/ (last visited Dec. 5, 2002).
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landmark moment for women's health research. Researchers were put on
notice that they would be held accountable for upholding previously
enacted policies that encouraged the inclusion of women in clinical trials.
Public outrage over the implications of missing information on women
fueled the work of congressional champions of the issue. A month after the
release of the GAO report, the Congressional Caucus on Women's Issues
introduced the Women's Health Equity Act of 1990 (WHEA).& This
legislative response consisted of twenty separate bills designed to improve
research on women's health issues, women's access to health care, and
disease prevention services for women. WHEA's chief Senate sponsor,
Senator Barbara Mikulski (D-MD), attached three provisions to legislation
reauthorizing NIH funding which created an office specifically devoted to
women's health research at NIH, required that women be included in
clinical trials, and established five contraceptive and infertility research
centers.2 1 Of all the provisions included in the bill, only two-the Breast
and Cervical Cancer Mortality Prevention Act and Medicare coverage for
screening mammography-were passed at that time."
Also as a result of the 1990 GAO report and the outcry it provoked in
Congress, NIH instituted guidelines for grant submission that required the
inclusion of women as research subjects unless there was a clear
justification for their exclusion. 3 These guidelines became law in 1993 with
the passage of the 1993 NIH Revitalization Act, 4 which contained language
requiring the inclusion of women in medical research 2 and the analysis of
resulting data by sex.26 This language differs from the 1985 guidelines, as
the earlier guidelines simply encouraged, but did not require, the inclusion
of women in clinical trials. By requiring the inclusion of women, the new
20. Women's Health Equity Act of 1990, H.R. 5397, 101st Cong.; Women's Health
Equity Act of 1990, S. 2961, 101st Cong.
21. Id.
22. Lesley Primmer, Women's Health Research: Congressional Action and Legislative Gains:
1990-1994, in WOMEN's HEALTH RESEARCH, supra note 8, at 308.
23. Guideline for the Study and Evaluation of Gender Differences in the Clinical
Evaluation of Drugs, 58 Fed. Reg. 39,406 (July 22, 1993).
24. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical
Research, 59 Fed. Reg. 14,508 (Mar. 28, 1994).
25. The 1994 NIH guidelines state that "it is the policy of NIH that women and
members of minority groups and their subpopulations must be included in all... projects
involving human subjects." Id. at 14,509.
26. The 1994 guidelines stated that "[f or Phase III clinical trials, [the NIH must]
ensure that women and minorities and their subpopulations must be included such that
valid analyses of differences in intervention effect can be accomplished." Id. at 14,508.
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legislation was a major policy shift in biomedical research. Scientists could
no longer categorically deny women access to clinical trials; instead they
had to provide a scientific argument to justify women's exclusion.
The 1990 GAO report on the inclusion of women in NIH-sponsored
research was followed by a 1992 report on the practices of the FDA in
approving prescription drugs. The 1992 report found that while women
were sometimes included in drug trials, they were underrepresented.2 ' The
study reported that "for more than 60 percent of the drugs, the
representation of women in the test population was less than the
representation of women in the population with the corresponding
disease." 8 Even when women were included in large numbers, data were
not analyzed to determine if women's responses differed from those of
men. Further, drug manufacturers often failed to study whether their
drugs interacted with the different hormonal environment of a woman's
body. The report concluded by recommending that the FDA should
ensure that drug companies consistently include "sufficient numbers of
women in drug testing to identify gender-related differences in drug
response and that such differences are explored and studied.",", As a result
of this report, the FDA lifted its restriction regarding the inclusion of
women of childbearing potential in clinical trials and formalized
guidelines regarding the analysis of data by sex.'o
C. Clinical Trials and the Pregnant Woman
The regulatory changes of the 1990s resulted in greater access to
clinical trials for women. By the year 2000, the number of women in
federally funded clinical trials was proportionate to their numbers in the
general population.3' The inclusion of pregnant women, however,
remained an especially thorny issue. In 1975, the federal regulations
governing the use of human subjects in research were amended to reflect a
perceived need to afford special protection to fetuses and potential fetuses,
effectively treating the fetus as a vulnerable research subject who could not
27. U.S. GEN. ACCOUNTING OFFICE, GAO-HRD-93-17, WOMEN'S HEALTH: FDA NEEDS To
ENSURE MORE STUDY OF GENDER DIFFERENCES IN PRESCRIPTION DRUGS TESTING (1992).
28. Id. at 2-3.
29. Id. at 12.
30. See Guideline for the Study and Evaluation of Gender Differences in the Clinical
Evaluation of Drugs, 58 Fed. Reg. 39,406 (proposed July 22, 1993).
31. U.S. GEN. ACCOUNTING OFFICE, GAO/HEHS-00-96:2, WOMEN'S HEALTH: NIH HAS
INCREASED ITS EFFORTS To INCLUDE WOMEN IN RESEARCH (2000).
111:2 (2003)
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give consent.3- This change had the result of diminishing women's
autonomy in deciding whether to assume the risk of participation in a
clinical trial, regardless of whether or not she was pregnant. In 1991, the
emphasis shifted from fetal protection to respect for women's autonomy
when the Supreme Court ruled in UAW v. Johnson Conlrols, Inc. that a
woman has the right to be involved in decisions concerning fetal risk!"
This ruling supported the Pregnancy Discrimination Act of 1978,1 which
stated that decisions about the welfare of future children should be left to
the parents who conceive, bear, support, and raise them. In both instances,
the Court and Congress supported a woman's ultimate right to make the
decision about accepting risks that may be potentially harmful to her
reproductive status.' Assuming that a woman is given appropriate risk
information, one would assume that she is as capable of making decisions
about participation in clinical trials as she is of making decisions about
employment.
In May of 1998, during the Clinton administration, the United States
Department of Health and Human Services (HHS) published a proposed
change to federal regulations 1 that would have allowed pregnant women
to be included in clinical trials. 7 Essential to this rule was the policy of not
requiring paternal consent for a pregnant woman to participate in
research . In the past, paternal consent had been a barrier to the
participation of woman or fetuses in research.n9 In reviewing the Proposed
Rule, organizations such as the National Task Force on AIDS Drug
Development, the Presidential Advisory Council on HIV/AIDS, and the
Institute of Medicine's Committee on the Ethical and Legal Issues Relating
32. Protection of Human Subjects, 40 Fed. Reg. 33,526 (Aug. 8, 1975) (to be codified at
45 C.F.R. pt. 46).
33. UAW v.Johnson Controls, Inc., 499 U.S. 187 (1991); see also Ruth B. Merkatz &
Elyse 1. Summers, Including Women in Clinical Trials: Policy Changes at the Food and Drug
Administration, in WOMEN'S HEALTH RESEARcH, supra note 8, at 274.
34. 42 U.S.C. § 2000e(k) (2000).
35. See Merkatz, supra note 33, at 274.
36. 45 C.F.R. pt, 46.
37. Protection of Human Research Subjects, 63 Fed. Reg. 27,794 (proposed May 20,
1998) (to be codified at 45 C.F.R. pt. 46). This legislation reversed a 1977 ruling which
excluded women of childbearing potential from participating in clinical trials. See also U.S.
DEP'T HEALTH & HuMAN SERvs., supra note 11; Honig, supra note 12.
38. The issue of paternal consent will be discussed in more detail below. See infra
Section II.D.
39. See Protection of Human Research Subjects, 63 Fed. Reg. 27,794 (proposed May 20,
1998) (to be codified at 45 C.F.R. pt. 46).
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to Inclusion of Women in Clinical Studies, agreed unanimously that the
participation of pregnant women in research should not be conditioned
on paternal consent." The Final Rule, which was published in January
2001, concluded "the decision making authority for research participation
of the pregnant woman or fetus prior to delivery should rest with the
pregnant woman."'" By making the pregnant woman the sole decision-
maker, the regulation based the participation of pregnant women in
research on a policy of presumed inclusion, rather than presumed
exclusion.
Scheduled to take effect in March 2001, this regulation was delayed as
the incoming Bush administration considered several modifications, one
of which specifically addressed paternal consent.42 The proposed
modification would have required a father's consent for participation in
research that was directed solely at the fetus and that would not affect the
mother's health. The father's consent, however, would not be needed for a
woman to participate in research that would benefit her own health .4
This distinction is largely apocryphal as one cannot generally separate
the health of the mother from that of the fetus."4 As one policy expert
stated, "Fetuses may be more vulnerable than adults, but no hazards affect
exclusively fetuses. "45
After reviewing public comment on the modification, HHS adopted
the modification into the final replacement rule on November 13, 2001
and retained the language specifying that paternal consent would be
required for participation in research directed solely at the fetus .4 The
final rule did add language specifying that paternal consent is not required
in the case of rape or incest and that only maternal consent is needed for
participation in research that may benefit both the mother and the fetus or
only the mother. In cases where research is aimed only at the fetus,
paternal consent is required for participation.
40. Protection of Human Research Subjects, 66 Fed. Reg. 3879 (Jan. 17, 2001) (to be
codified at 45 C.F.R. pt. 46).
41. Id. at 3880.
42. Protection of Human Research Subjects, 66 Fed. Reg. 35,576 (proposed July 6,
2001) (to be codified at 45 C.F.R. pt. 46).
43. Id.
44. Id. at 56,776.
45. Ruth Hubbard, The Politics of Fetal/Maternal Conflict, in POWER AND DECISION: TfiE
SOCIAL CONTROL OF REPRODUCTION 311 (Gita Sen & Rachel C. Snow eds., 1994), available at
http://w-vw.hsph.harvard.edu/Organizations/healthnet/gender/docs/hubbard.html.
46. Protection of Human Research Subjects, 66 Fed. Reg. 56,775 (proposed Nov. 13,
2001) (to be codified at 45 C.F.R. pt. 46).
111:2 (2003)
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D. Criticism of the Women's Health Movement and the Response to that Criticism
As a result of legislation and policies to make medical research more
widely available to women, the number of women included in clinical trials
has increased. As mentioned above, a report issued by the GAO in 2000
found that women are being included in clinical trials at rates
proportionate to their numbers in the general population. ' 7 The report
found that "the review process for extramural research now treats the
inclusion of women and minorities as a matter of scientific merit ... and it
appears that NIH staff and researchers are working to ensure that, when
appropriate, study findings will apply to both women and men."48
With success, however, comes criticism. Critics cite the increasing
numbers of female participants in NIH-funded clinical trials as evidence
that attention to women's health has come at the expense of attention to
men's health.4 Many of these critics have based their arguments on the
findings of a 2000 study by Curtis Meinert, which concluded that prior to
1993, women had not been excluded from clinical trials .'0 A small number
of vocal opponents to the women's health movement saw the 2000 GAO
report and Meinert's article as opportunities to lambaste policies aimed at
promoting a women's health agenda.5' However, the findings from this
single study are contradicted by those of several other studies that did find
a bias against the inclusion of women in clinical trials52 but did not gain as
47. See U.S. GEN. ACCOUNFING OFFICE, supra note 31.
48. Id. at 2.
49. EXPLORING THE BIOLOGICAL CONTRIBUTIONS TO HUMAN HEAL -Ii: DOES SEX MATTER?,
(Theresa M. Wizemann & Mary-Lou Pardue eds., 2001), available at
http://bookshop.edu/books/0309072816/html; Edward E. Bartlett, NIH Is Playing Fast and
Loose with the Truth, MEN'S HEALTH AM., at
http://groups.yahoo.com/group/menshealth/message/157 (last visited on Dec. 4, 2002);
Cathy Young, Medical Gender Wars, SALON, available at
http://dir.salon.com/health/feature/2000/09/20/ womenshealthi (last visited on Dec.
4, 2002); Cathy Young, It's Time To End the Gender Gap in Health Care, BOSTON GLOBE, Nov.
15, 2000, at A27.
50. Curtis L. Meinert et al., Gender Representation in Trials, 21 CONTROLLED CLINICAL
TRIMS, 462-75 (2000).
51. See ExPLORING THE BIoLoOGICAL CONTRIBUTIONS TO HuMAN HEALTH, supra note 49;
Satel, supra note 49; Young, supra note 49; Bartlett, supra note 49.
52. Kathryn Graff Low et al., Women Participants in Research: Assessing Progress, 22
WOMEN'S HEALTH 79-98 (1994); Mary McGrae McDermott et al., Changes in Study Design,
Gender Issues, and Other Characteristics of Clinical Research Published in Three Major Medical
Journalsfrom 1971 to 1991, 10J. GEN. INTERNAL MED. 13-18 (1995); Douglas L. Schmucker &
9
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much exposure in the popular press as did Meinert's.
Meinert also asserts that "within broad limits, treatments shown to
work in one gender group also work in the other gender group."" This
conclusion was soundly refuted in the Institute of Medicine's 2001
landmark report, Exploring the Biological Contributions to Human Health: Does
Sex Matter?.54 In the mid-1990s, a consortium of public and private
sponsors, led by the Society for Women's Health Research, initiated and
sponsored the formation of the Institute of Medicine's (10M) Committee
on Understanding the Biology of Sex and Gender Differences. The
Committee was charged with considering the biology of sex at the cellular,
developmental, organ, organismal, and behavioral levels. The IOM report
concluded that:
There is now sufficient knowledge of the biological basis of sex
differences to validate the scientific study of sex differences and to allow
the generation of hypotheses .... Naturally occurring variations in sexual
differentiation and development can provide unique opportunities to
obtain a better understanding of basic differences and similarities
between and within the sexes.
Figure 1 provides a list of a few of the sex differences highlighted in the
IOM report.
The exploration of sex differences in medical research is not purely an
academic concern. Missing information on sex differences has serious
health implications for women. A 2001 report by the GAO found that eight
of ten prescription drugs that had been withdrawn from the United States
market since january 1997 caused serious adverse reactions more often in
women than in men.t Four of these drugs were prescribed with equal
frequency to men and women, suggesting that the greater health risks in
women were possibly due to physiological differences between women and
men that predispose women to some drug-related health risks, including
Elliot S. Vesell, Underrepresentation of Womien in Clinical Drug Trials, 54 CLINICAL
PtHARMACOLOGY & THERAPEUTICS 11 (1993); Regina M. Vidaver et al., Women Subjects in NIH-
Funded Clinical Research Literature: Lack of Progress in Both Representation and Analysis by Sex, 9 J.
WOMEN'S HEAiTH GENDER BASED MED. 495-504 (2000).
53. Curtis L. Meinert & Adele Kaplan Gilpin, Estimation of Gender Bias in Clinical Ttials,
20 SlAT. MED. 1153, 1163 (2001).
54. See EXPLORING THE BIOLOGICAL CONTRIBUTIONS TO HUMAN HEALTH, supra note 49.
55. See id. at 3.
56. U.S. GEN. ACcOUNTING OFFIcE, GAO-01-286R, DRUG SAFElY: MOST DRUGS
WITHDRAWN IN RECENTYEARS HAD GREATER HEALTH RISKS FOR WOMEN 2 (2001).
111:2 (2003)
10
Yale Journal of ealth Policy, Law, and Ethics, Vol. 3 [2003], Iss. 2, Art. 2
https://digitalcommons.law.yale.edu/yjhple/vol3/iss2/2
SEX & GENDER IN MEDICAL RESEARCH
Torsades de Pointes (TdP), a potentially fatal cardiac arrhythmia (TableI .57
Other studies support the GAO findings. For example, one study
found that the commonly prescribed antibiotic erythromycin causes TdP
more often in women."" The investigators concluded that greater serum
concentrations of erythromycin in women were not to blame for the
increased risk of TdP; rather, the rate of erythromycin metabolism is
higher in women, thereby mitigating the differences in body size and
blood volume, " Some experimental studies have suggested that sex
hormones, such as estrogen, can alter myocardial repolarization,
potentially prolonging the QT interval,"" leading to TdP.tt Other studies,
however, suggest that the effects of estrogen are not likely to be
responsible for the gender differences seen in myocardial repolarization. 2
Conflicting findings such as these highlight the need for further research
in the field of sex-based biology.
Sex differences in drug metabolism have serious implications for the
drug development and approval process. For example, in one study of
steroid-dependent Crohn's disease, researchers used separate parameters
for drug clearance (the rate at which the body metabolizes a drug)--one
for males and one for females.6' They also used covariants such as lean
body weight to take into account the volume of drug distribution. They
found that for a given dose of the study drug, males in the study had a
57. Id. at 24.
58. Milou-Daniel Drici et al., Cardiac Actions of Eiythromycin: hflumnce of Female Sex, 280
JAMA 1774, 1774-76 (1998).
59. Id. at 1776.
60. The QT interval is a measurement made from the electrocardiogram (ECG or
EKG). It reflects the duration of the electrical activity that controls contraction of the cells
of the heart muscle. For more information, see Ariz. Ctr. for Educ. & Res. on Therapeutics,
Commonly Asked Questions, al http://www.qtdrugs.org/consnmers/ask-expert.htm (last
visitedJan. 21, 2003).
61. Milou-Daniel Drici et al., Sex Hormones Prolong the QT Interval and Downregdate
Potassium Channel Expression in the Rabbit Heart, 94 CIRCULATION 1471, 1473-74 (1996); M.
Pragnell et al., Estrogen Induction of a Small, Putative K+ Channel mRVA in Rat Uterus, 4
NEURON 807 (1990).
62. jennifer A. Larsen et al., Effects of Hormone Replacement Therapy on QTInterval, 82 Am.
J. CARDIOLOGY 993, 993-95 (1998).
63. Helen Pentikis, Detecting PK Differences in Phase I trials (2001) (paper presented
at Subgroup Analysis and Statistical Design for Detecting Sex Differences: Detecting Sex
Differences in Clinical Trials, conference sponsored by the Society for Women's Health
Research) (on file with author).
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lower maximum concentration of the drug than did females. Further, they
concluded that weight normalization for dosing did not provide for equal
exposure for this particular drug and that dosing should have been
stratified by sex. Despite this important information, the study sponsor did
not want separate dosing recommendations for males and females for fear
it would be more difficult to market the drug with differential dosing4 As
this drug failed to show efficacy at a single dose, the study sponsor elected
not to market it.c5
In another study, a lipid protease inhibitor failed to show efficacy in
reducing damage from infarcts of the brain.':  When looking at the
pharmacokinetic (PK) and pharmacology data in retrospect, however,
there is reason to believe that the women in the study were simply under-
dosed. The clearance rate for the drug was 149 percent greater in women
than in men, meaning that on average, for a given dose, women achieved
only two-fifths the blood, tissue, and brain levels of the drug that men did.
In this case, the study sponsor decided not to move forward with
developing the drug and a potentially beneficial therapy was lost.
67
As demonstrated by these examples, the inclusion of more women in
clinical trials without appropriate analysis of data by sex serves political
purposes but does little to improve our knowledge of women's health. The
2001 reports from the IOM and GAO emphasize that analyzing data by sex
is critical for advancing our knowledge of human health.
II. POLICY SUGGESTIONS AND IDEAS FOR THE FUTURE
A. Improving Recruitment and Retention
Women are now increasingly included in clinical trials, but much can
still be done to encourage women to volunteer for and remain in trials.
Research has found that public misperceptions, mistrust of medical
research, and fear of clinical trials are major barriers to participation in
trials for both men and women. Potential subjects often believe that
participating in a research trial means that they will receive general
64. Id.
65. Id.
66. Carl Peck, Detecting Sex Differences Ethically and Efficiently in Phase I/II Trials
(2001) (paper presented at Subgroup Analysis and Statistical Design for Detecting Sex
Differences: Detecting Sex Differences in Clinical Trials, conference sponsored by the
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medical care. They may be disappointed to learn that they are only
receiving medical care related to the study. Additionally, participants may
drop out of a study if they believe they are receiving a placebo or less
efficacious form of a drug or therapy. The fear of numerous visits,
unpleasant side effects, or complicated regimens that can interfere with,
work or family responsibilities can also prevent women from enrolling in
medical studies."" Examples of research misconduct, such as the infamous
United States Public Health Service Syphilis Study (known as "The
Tuskegee Study"69) have led to fear and distrust of the medical system,
resulting in lower enrollment rates." To address this problem, investigators
and recruiters must be frank with participants about the specifics of a
study, realistic about the expected costs and benefits from the trial, and
focused on conducting a trial safely and ethically.
Researchers often cite the difficulty of recruiting and retaining female
subjects in clinical trials as one reason why women are not sufficiently
included in studies. Beyond the barriers mentioned above, there are
additional barriers that are of special concern for women. These include
lifestyle and logistical issues, concerns about participation risks, potentially
onerous requirements for fetal protection, and unmanageable time
commitments required by the study protocol." Traditionally, women have
been the primary caregivers for family members. As such, participation in a
clinical trial may significantly impact a woman's ability to care for her
family. Minimizing time and safety barriers for women can have a
significant effect on increasing their participation in clinical trials.72
Overcoming lifestyle and logistical issues requires that investigators
consider critical questions during the study planning and implementation
phases such as:
* Has study protocol minimized the number of study visits?
* Is the site open evenings or weekends?
* Can the site provide childcare during study visits?
Does the site offer convenient parking and access to public
68. Donna Rae Richardson, The Retention of Women in Clinical Trials: Lifestyle Issues Unique
to Women, in THE SOCIETY FOR WOMEN'S HEALTH RESEARCH, PROCEEDINGS FROM WOMEN AND
CLINICAL RESEARCH: BREAKING THROUGH THE BARRIERS TO RECRUITMENr AND RETENTION 22
(2001).
69. JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT (1993).
70. Id.
71. Soc'y for Women's Health Res., The Participation of Women in Clinical Trials: A
Review of the Literature. (Apr. 1999) (unpublished data, on file with author).
72. Richardson, supra note 68, at 23-24.
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transportation?
" Is the site located in a safe area?
" How can long waiting times during visits be reduced or avoided?7"
Further, investigators should be cognizant of the potential impact of a
study on a woman's responsibilities in the home.74
Study sites that have successfully retained women have done so by
paying close attention to women's needs and concerns. Female
participants value the relationships they develop with study staff and
appreciate staff attention to events in their lives. Fostering such a
relationship can be done with little added expense by simply taking note of
events that a study participant mentions during visits. 75 These may be family
events such as births, illnesses or deaths, or an upcoming vacation or
anniversary. Other strategies may include sending birthday cards or
valentines to participants, or creating newsletters and other ways to
maintain contact between study visits.76 Even in populations of hard-to-
reach women, attention to their special needs results in exceptional
retention rates. In one study of an HIV prevention and vaccine trial,
researchers had a retention rate of ninety-two percent after the first year of
the study.77 What makes this retention rate so exceptional is that the study
population consisted of poor, disenfranchised women, many of whom had
moved repeatedly, or were using illegal drugs.7 ' The researchers attributed
their success to the support they provided these women in the form of a
shoulder to cry on, toiletries for the homeless and incarcerated, and
referrals to social services for housing, drug treatment, domestic violence,
welfare or other services. In addition, they concluded that study design
requires one full-time staff person whose job was to focus solely on
retention issues.
7
To overcome public fears and misperceptions of medical research
among both men and women, organizations and agencies have initiated
73. Id.
74. See Soc'y for Women's Health Res., supra note 71.
75. See Richardson, supra note 68.
76. Id.
77. Pamela Brown-Peterside et al., Retaining Hard-to-Reach Women in H1V Prevention and
Vaccine Trials: Prject A CHEVE. 91 AM. J. PUB. HEALTH 1377 (2001).
78. Pamela Brown-Peterside, The Retention of Women in Clinical Trials: Outreach to the
-lard-to-Reach, in THE SOCIETY FOR WOMEN'S HEALTH RESEARCH, PROCEEDINGS FROM WOMEN
AND CuNICAL RESEARCH: BREAKING THROUGH THE BARRIERS TO RECRUITMENT AND RETENTION
24 (2001).
79. See Brown-Peterside, supra note 77, at 1378.
111:2 (2003)
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public education efforts and organized on-line resources for locating
studies. NIH maintains a database of all federally-funded research studies.
Patients and potential study participants can search this database at
www.clinicaltrials.gov. On-line listings of clinical trials and information on
participating can also be found at www.womancando.org"' and
www.centerwatch.com. All three websites contain information about what
clinical trials are, who can participate, and how to make a decision about
participating.
There is early evidence that web-based education may increase
enrollment rates. Results from a recent Harris Poll and Boston Consulting
Group study show that that the more frequently a patient uses the Internet
to seek health information, the stronger his/her response to "the call to
action issued by health care companies. "8' The researchers found that
"those who use the Internet frequently are two to three times more likely
than infrequent users to take action that affects their diagnosis and
treatment. ""2 Logic would dictate that the more often patients use the
Internet to research clinical trials, the more likely they are to participate.
It is important to note that strategies for promoting the recruitment
and retention of women in clinical trials can be applied to other under-
represented populations such as minorities and the elderly. Specifically,
effective recruitment and retention strategies will take into account the
knowledge, attitudes, and beliefs of potential study volunteers, as well as an
assessment of potential barriers to continuing participation once a
volunteer is enrolled. For example, extensive outreach by investigators to
community leaders can help to overcome mistrust within minority
communities. Researchers must be aware that normal effects of aging (for
80. The Society for Women's Health Research's "Some Things Only a Woman Can Do"
public education campaign (www.womancando.org) provides tools for physicians and
researchers to educate potential study volunteers about research and participation in
studies. The campaign distributes printed information (available by calling a toll-free
number), maintains an Internet site, and coordinates outreach to the print and broadcast
media to reach women throughout the United States.
81. Harris Interactive, eHealth Paradox: It's Harder to Reach Patients Online Than To Have
an Effect on Them, IIXRIS INTERACT vE NEWsL. (July 2, 2001), available at
http://www.harrisinteractive.com/news/alnewsbydate.aspNewslD=326.
82. Id.
83. Katherine Pitkin Derose et al., Dealing with Diversity: Recruiting Churches and Women
for a Randomized Trial of Mammography Promotion, 27 HEmTHi EDuc. BEHAV. 632, 643-44
(2000); Shawkat Dhanani et al., Community-based Strategies for Focus Group Recruitment of
Minority Veterans, 167 MIL. MED. 501, 504 (2002); Marion K. Slack et al., Strategies Used b,
Interdisciplinary Rural Health 7raining PI-ograms To Assuwe Community Responsiveness and Recruit
15
Keitt: Sex & Gender: The Politics, Policy, and Practice of Medical Research
Published by Yale Law School Legal Scholarship Repository, 2003
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
example, vision problems and mobility issues), chronic disease,
transportation needs, negotiations with caretakers such as family members,
and physician involvement can all impact recruitment and retention of
.e" 4elderly subjects. It has become obvious that a one-size-fits-all approach to
recruitment and retention will limit a researcher's ability to recruit a
diverse study population.
B. Informed Consent and the Use of Contraceptives
For any woman, pregnant or not, a thoughtful and honest informed
consent process is critical to increasing the participation rate of women in
clinical trials. During the informed consent process the research staff is
responsible for informing a woman of potential risks to both her and her
potential fetus and providing her with information about all available
options in the event of pregnancy. A 1999 study found, however, that
"investigators often omit fetal risk information from consent documents."5
Without full disclosure of fetal risks, a woman of childbearing potential is
unable to make a truly informed decision about her enrollment in a
clinical study."
Concern about fetal risk may also lead to enrollment requirements
that pose an undue burden on female participants, such as the use of
contraception methods that the participant may not find acceptable or
affordable. Researchers and study sponsors often struggle with how to
communicate risk effectively, and one means of reducing risk in cases with
clear evidence of fetal risk, or with an unknown potential for risk, is to
require women who are heterosexually active and who are not surgically
sterile or postmenopausal to use effective contraception. This approach,
however, limits access to trials for women who do not use birth control for
economic, medical, moral, or religious reasons. Further, there may be
limitations to what constitutes "effective" contraception. For example,
hormonal contraception may alter the pharmacokinetics and
pharmacodynamics of the drug being studied and may make it difficult to
PractitionerT, 16J. INTERpROF. CARE 129 (2002).
84. Elizabeth A. McNeely & Sandra D. Clements, Recruitment and Retention of the Older
Adult into Re5earch Studies, 26J. NEUROSURGERY NURSING 57, 58-59 (1994).
85. Marie T. Nolan et al., Consent Documents, Reproductive Issues, and the Inclusion of
Women in Clinical Tria&, 74 ACAD. MFD. 275, 275 (1999).
86. Dale Hammerschmidt, Ethical Issues in Recruitment: Navigating the Informed Consent
!-ocess Responsibly, in THE SOCIETY FOR WOMEN'S HEALTH RESEARCH, PROCEEDINGS FROM
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separate the side effects of the study medication from the side effects of
hormonal contraception. 7 Certain drugs can also alter the effectiveness of
hormonal contraceptives. 8 Unfortunately, non-hormonal contraceptive
methods such as condoms, diaphragms, periodic abstinence, and
withdrawal have failure rates between thirteen and twenty-eight percent.
89
An important study found that informed consent documents routinely
spelled out the requirement that female participants use contraception,
but did not provide adequate justification for such a requirement.
0 When
a study does require the use of contraception, the explanations for this
requirement should be offered in a manner that is respectful of a woman's
autonomy in deciding which contraception methods to use. Women for
whom contraceptives would be an unnecessary burden (for example,
religious women who have taken vows of celibacy, women whose partners
have been surgically sterilized, and lesbians) should not be required to use
them. If the study involves compulsory pregnancy testing, this requirement
should be clearly explained to women during the consent process.91
C. Pregnancy and the Clinical Trial
Because women of reproductive potential are now included in clinical
trials, there is the potential for some of these women to become pregnant
while participating in a study. Pregnancy during a clinical trial opens up
new concerns and risks-including practical issues such as the unknown
effects of pregnancy on the pharmacokinetics and pharmacodynamics of a
drug, and the ethics of continuing the administration of a study
medication with unknown reproductive risks. However, the 1994 report
from the IOM concluded that the lack of information regarding safe
treatment options for pregnant women has its own set of concerns and
risks. The Committee recommended that "NIH strongly encourage and
facilitate clinical research to advance the medical management of pre-
existing medical conditions in women who become pregnant (e.g., lupus),
medical conditions of pregnancy (e.g., gestational diabetes), and
87. 1 WOMEN AND HEALTH RFSEARCH 185 (Anna C. Mastroianni et al. eds., 1994),
available at http://www.nap.edu/books/030904992X/html/.
88. Mark S. Yerby, Special Considerations for Women with Epilepsy, 20 PHARMAcOTHERAvtN
159S, 159S (2000).
89. Haishan F1 et al., Contraceptive Failure Rates: New Estimates from the 1995 National
Survey of Family Growth, 31 FAM. PLAN. PERSp. 56, 56 (1999).
90. Joanna Cain et al., Contraceptive Requirements for Clinical Research, 95 OBSTETRILS &
GYNECOLOGY 861, 861 (2000).
91. See Hammerschmidt, supra note 86, at 12.
17
Keitt: Sex & Gender: The Politics, Policy, and Practice of Medical Research
Published by Yale Law School Legal Scholarship Repository, 2003
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
conditions that threaten the successful course of pregnancy (e.g., pre-term
labor)."' As outlined in the Belmont Report, the principal of respect for
persons requires that research subjects be given the opportunity to choose
what will and will not happen to them.3 Therefore, a truly informed
participant, aware of the potential risks to her and to her fetus, should be
allowed to make her own decisions about continuing in a study. It is more
unethical to deny her the autonomy to make her own medical decisions
than it is to force her to quit in the name of fetal health.
D. Paternal Consent
The regulation discussed above requiring paternal consent before a
pregnant woman can participate in a trial aimed at the health of the fetus
94
is based on the assumption that one can separate the mother's health from
that of the fetus. Arguments for requiring paternal consent were
summarized in a 1994 IOM report:
The committee recognizes that the husbands of pregnant women, as well
as future fathers who are not husbands, have an interest in the health of
their children and that these men may have a deep emotional
attachment toward their offspring prior to birth. Until a child is born
however, the future father can only protect the health of the potential
child by controlling the decisions and actions of the woman.
The IOM concluded that "[t]o give men the authority to veto the
decisions of their wives or partners to participate in research grants men
unacceptable power over women."' This position is also supported by the
Scientific and Ethical Review Group (SERG) of the World Health
Organization, which stated, "A requirement of partner agreement or
authorization for an individual to participate in research violates the
autonomy of research subjects and their right to confidentiality. ""7 By
92. WOMEN AND HFALTH RESEARCH, supra note 87, at 16.
93. Nat'l Comm'n for the Prot. of Human Subjects of Biomedical and Behavioral
Research, The Belmont Report: Fthical Principles and Guidelines for the Protection of Human
Subjects of Research (Apr. 18, 1979), http://ohsr.od.nih.gov/mpa/belmont.php3#xethical.
94. Protection of Human Research Subjects, 66 Fed. Reg. 35,576 (proposed July 6,
2001) (to be codified at 45 C.F.R., pt. 46).
95. WOMEN AND HEAL!Iii RESEARCH, supra note 87, at 197.
96. Id.
97. World Health Org., Guidelines on Reproductive Health Research and Partners' Agreement,
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requiring paternal consent for participation in medical research, one is
denying a woman the autonomy to make decisions about her health and
about what is to be done to her body.
E. Improving Statistical Design in Clinical Trials and the Need for Accurate Drug
Labeling
As discussed above," sex differences in drug trials may be missed in
early phase clinical trials because women are not included in numbers
great enough to detect statistically significant differences in drug effects.
So how can researchers avoid making such statistical errors in the analysis
of clinical trial data? One way is to include enough women to have a
sample size with enough power to be able to detect statistically significant
sex differences. Trials this size, however, are generally cost-prohibitive."
Industry experts fear that escalating costs for clinical trials will have the
effect of stalling medical research, as private companies will not be able to
recoup research and development costs."'
But there are alternatives to large, costly trials. Dr. Carl Peck of
Georgetown University recently proposed a method for conducting Phase I
clinical trials in a manner that is both ethical and cost efficient. Safety and
dosing information is determined in Phase I trials. These early trials
generally have a small sample size (between ten and twenty subjects) and
are usually conducted on men.'01 Peck proposes testing an investigational
drug first in a small number of men and then testing it in a smaller
number of women to determine if the women's results vary from those of
the men. Using Bayesian analysis methods to compare the distribution of
these results, 112 one could then determine if the females' distribution of
drug responses differed from that of the males. If it did, then one would
need to conduct a separate study in women to determine appropriate
dosing and efficacy data. If their distributions were the same, one could
then proceed to Phase II trials under the assumption that there were no
sex differences in the metabolism of the drug.0 3
Innovative approaches to statistical analysis such as this can pave the
98. See Peck, supra note 66; Pentikis, supra note 63; discussion infra Section II.D.
99. See Peck, supra note 66.
100. Tom Hollan, What Woinm Want: Taking Sex Differences Seriously in Clinical Trials, 1
CuNICAL RESEARCHER 24 (2001).
101. See Peck, supra note 66.
102. For an explanation of Bayesian analysis, see Will Hively, The Mathematics of Making
Up Your Mind, 1996 Discover 90, available at http://www.discover.com/archive/index.html.
103. See Hollan, supra note 103, at 26.
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way for drug sponsors to conduct clinical research that is relevant to
women, without significantly increasing drug development costs. 4 Action,
however, must also be taken in order to ensure that once sex differences
are detected, information about these differences makes its way into drug
labeling. It is easier to market a drug that has a one-size-fits-all dosing
regimen."° Currently, there are very few incentives, and no requirements,
for drug companies to have different dosing regimens or patient
information sheets for men and women. Even when pharmacokinetic and
safety data are available, the FDA does not require this information to be
included in product labeling.' 6
A recent study by the FDA demonstrates the pressing nature of the
drug labeling problem. The study examined the labeling for new drugs
approved between 1995 and 1999. Of the 185 product labels analyzed for
this study, twenty-two percent of the labels stated that there were sex
differences for the drug. Ten percent stated that no studies were
performed, studies were inadequate, retrospective review showed no
differences, or that the product was not indicated in a specific gender.
Thirty-two percent of the labels had no statements about sex.' 7 Of the
forty-one products for which the labels did describe sex differences, most
(ninety percent) were pharmacokinetic. Twelve percent were safety
differences and five percent were related to efficacy.'6 Of all 185 products
reviewed, not one reported a change in dosage based on sex differences-
despite the fact that thirty-seven of these products had known sex
differences in their PK properties. '9
F. Pharmacogenomics
Learning more about sex differences is just one step toward improving
health care for both men and women. The sex of a patient may soon
become a critical piece of information used by clinicians in deciding which
antidepressant, cardiac drug, or painkiller to prescribe."0 These exciting
104. See Peck, supra note 66.
105. Id.
106. B. Evelyn et al., Women's Participation in Clinical T7ials and Gender Related Labeling: A
Review oJ New Molecular Entities Approved 1995-1 999 (2001), available at
http://www.fda.gov/cde/reports/womens-healt/women clin-trials.html (last visited
Mar. 24, 2003).
107. Id. at 11.
108. Ad. at 13.
109. Id.
110. Deborah Gesensway, Reasons for Sex-Specific and Gender-Specific Study of Health Topics,
111:2 (2003)
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discoveries are the building blocks for even greater advances in the field of
medicine. The nascent field of pharmacogenomics, the science of
examining the inherited variations in genes and how these variations can
be used to predict an individual's response to a drug," ' holds the promise
of allowing clinicians to tailor drug therapies to the individual patient, not
just to women or men. Advances in the field have led to new approaches to
treating disorders common in women, such as heart disease and breast
132cancer.
Pharmacogenomics may also reduce the incidence of adverse drug
reactions (ADRs) in both women and men. Some of these ADRs could be
prevented by changing prescribing practices for patients with a known
genetic mutation that negatively impacts treatment outcomes."" For
women, pharmacogenomics holds the promise of reducing the incidence
of cerebral-vein thrombosis (blood clots), a common ADR associated with
the use of oral contraceptives. Studies have shown that women who have
the G20210A mutation for the prothrombin gene have ten times the risk of
developing a blood clot as do women who do not have this mutation.14 For
all woman, taking oral contraceptives increases the risk of developing a
blood clot by a factor of approximately twenty. It has now been shown that,
in women who take oral contraceptives and have the prothrombin
mutation, the relative risk of thrombosis is increased to nearly 150.1 5 In the
future, physicians may screen women for this and other genetic mutations
before they are prescribed oral contraceptives. Women with susceptible
genetic mutations would then have the option of using other contraceptive
and therapeutic regimens. This is just one example of how
pharmacogenomics may be used to improve the health of women. As the
field matures, pharmacogenomics 411 offer the opportunity to better
understand the pathogenesis of diseases and to improve sub-optimal drug
135 ANNALS INTERNAL MED. 935 (2001).
111. Nat'l Ctr. for Biotechnology Info., Nat'l Inst. of Health, One Size Does Not Fit All: The
Promise of Pharmacogenomics (Feb. 13, 2003), at
http://www2.ncbi.nlm.nih.gov/About/primer/pharm.html.
112. Francis S. Collins & Victor A. McKusick, Implications of the Human Genome Project for
Medical Science, 285 JAMA 540 (2001); Francis S. Collins, Medical and Societal Consequences of
the Human Genom Project, 341 NEw ENG. J. MED. 28 (1999),
113. Kathryn A. Phillip et al., Potential Role of Pharmacogenomics in Reducing Adverse Drhug
Reactions: A Systematic Review, 286JAMA 2270 (2001).
114. 1. Martinelli et al., High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene
Mutation and in Users of (O'al Contraceptives, 352 NEw ENG.J. MED. 1793 (1998).
115. Id.
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therapies for each sex. 6
II1. CONCLUSION
As the nascent field of pharmacogenomics demonstrates, and the 2001
IOM report confirms, it is crucial for researchers to look for differences in
their study populations-whether they are differences related to gender or
differences between individuals. However, researchers will not be able to
detect these differences if study populations do not include appropriate
numbers of women and men of all ages and ethnicities.
The inclusion of women in clinical trials has been a major force in the
advancement of biomedical research. Paternalistic policies of the 1960s
and 197 0s gave way under pressure from the burgeoning women's health
movement, which instigated landmark reports by the U.S. Public Health
Service1 7 and the United States General Accounting Office.' These
reports led to changes in regulations regarding the inclusion of women in
federally funded research."9 As a result, by the late 1990s, record numbers
of women were participating in medical studies. The data from these
studies has finally resulted in the male norm of medical research being
dislodged. Investigators have come to realize that recruiting and retaining
women in research studies requires special attention to the unique needs
of women. The IOM has recognized the field of sex-based biology as a valid
scientific field of study.'20 Experts are urging the pharmaceutical industry
to collect pharmacokinetic and pharmacodynamic data for women as well
as men. 1 Statisticians and researchers are investigating novel methods for
conducting sex analysis of research data without bankrupting the system
with unwieldy study sizes."
Despite these advances, many issues remain regarding the inclusion of
women in clinical trials. Investigators still grapple with ethical issues
regarding paternal consent and the inclusion of pregnant women in
clinical trials. Even when it is collected, information about important sex
116. Francis S. Collins & Alan E. Guttmnacher, Genetics Moves into the Medical Mainstream,
286JAMA 2322 (2001).
117. See U.S. Pub. Health Serv., supra note 3.
118. See -Iearing, supra note 16.
119. Protection of Human Research Subjects, 66 Fed. Reg. 56,775 (proposed Nov. 13,
2001) (to be codified at 45 C.F.R. pt. 46).
120. See ExPLORING THE BIOLOGICAL CONTRIBUTIONS TO HuMAN HKALrH, supra note 49.
121. See Hollan, supra note 103.
122. See Peck, supra note 66.
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differences often does not make its way into drug labeling 3 or into the
medical literature.'11 There are signs, however, that this is changing. The
FDA is proposing major revisions in the format of the content of package
inserts to include information about sex differences,125 and several
prominent journals have begun requiring authors to include sex analysis in
their manuscripts. The Journal of the National Cancer Institute (]NCI)
specifically states in its information for authors that "Where appropriate,
clinical and epidemiologic studies should be analyzed to see if there is an
effect of sex or any of the major ethnic groups. If there is no effect, it
should be so stated in Results.' ' "
The wording of the editorial policy of the JNCI is particularly
noteworthy because it specifically states that negative results must be
reported. This is the antithesis of the more common practice of
suppressing negative results. "7 It should be noted that several studies have
found that publication bias (failure to publish negative findings) is
initiated by the investigator and is not due to editorial decisions.28 The
authors found that most unpublished negative findings remained so
because the investigators thought the results were uninteresting or they did
not have enough time to publish them. By requiring investigators to
include sex analysis results, even negative ones, in their manuscripts,
journals such as JNCI are reinforcing the message of the 2001 IOM report:
Sex does matter.
In the past fifteen years, women have made great strides in their
participation in clinical trials. As the barriers to appropriate representation
123. See EVELYN, supra note 109.
124. See Vidaver, supra note 52.
125. U.S. DEP'T HEALTH & HUmAN SERVS., FOOD & DRUG ADMIN., CTR. FOR DRUG
EVALUATION & RESEARCH, CTR. FOR BIOLOGICS EvALUATION & RESEARCH, GUIDANCE FOR
INDUSTRY: CONTENT AN) FORMAT OF THE ADVERSE REACTIONS SEC ION OF LABELING FOR
HUMAN PRESCRIPTION DRUGS AND BIOLOGICS (2000) (draft guidance), available at
http://www.fda.gov/cder/guidance/1888dft.pdf; see also Robert L. Woosley, Drug Labeling
Revisions: Guaranteed To Fail?, 284JAMA 3047, 3048 (2000).
126. Nat'l Cancer Inst., Information jot Authors for the.journal of the National Cancer Institute,
http://jncicancerspectrum.oupjournals.org/inisc/ jnci/ifora2.dtl (updated Mar. 13, 2003).
127. Kay Dickersin, How Important Is Publication Bias? A Synthesis of Available Data, 9 AIDS
EDUC. & PREVENTION 15 (Supp. A 1997); Philippa J. Easterbrook et al., Publication Bias in
Clinical Research, 337 LANCET 867 (1991).
128. Kay Dickersin & Yuan 1. Min, Publication Bias: The Problem that Won't Go Away, 703
ANNALS N.Y. ACAD. SCi. 135 (1993); Kay Dickersin et al., Factors Influencing Publication of
Research Results: Follow-up of Applications Submitted to Two Institutional Review Boards, 267 JAAIA
374 (1992).
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of women in medical research are being removed and more women
volunteer for medical studies, scientists are discovering important sex
differences that may lead to improved therapies and prevention strategies
for both men and women. More importantly, the greater inclusion of
women in clinical trails has led to more equitable research practices and
has begun to narrow the information gap regarding women's health.
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SEX & GENDER IN MEDICAL RESEARCH
Figure 1. Examples of Sex Differences Beyond the
Reproductive System.
Differences in Immune Function:
Females have a more aggressive immune response to infectious challenges, but
are also more likely than males to develop autoimmune diseases.
Differences in Symptoms, Type and Onset of Cardiovascular Disease:
Men experience heart attacks, on average, 10 years earlier and have a better early
survival rate than women. Symptoms of heart attack are also different in men and
women. Women more often experience shortness of breath, fatigue, and nausea,
while men more often experience crushing chest pain.
Differences in Response to Toxins:
Women are at 1.2- to 1.7-fold higher risk than men for all major types of lung
cancer at every level of exposure to cigarette smoke.
Differences in Brain Organization:
Men rely on the inferior frontal gyrus to carry out language tasks. Women use
both the left and right inferior gyrus to carry out the same task. Both men and
women perfbrm the task equally accurately and rapidly.
Adapted from "Box 1-2: Examples of Sex Difference Beyond the Reproductive System" in
Wizemann, supra note 53 at 22-23.
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Table I. Prescription Drugs Withdrawn from the United States
Market, Jan. 1, 1997 Through Dec. 31, 2000.
Drug Name Type of Drug Primary Health Risk
Prescription Drugs With Evidence of Greater Health Risks in Women
Drugs Prescribed with Equal Frequency to Men and Women
Seldane (terfenadine) Antihistamine Torsades de Pointes
Posicor Cardiovascular Lowered heart rate in elderly
(mibefradil women and adverse interactions
dihydrochloride) with 26 other drugs
Hismanal (astemizole) Antihistamine Torsades de Pointes
Propulsid Gastrointestinal Torsades de Pointes
(cisparide
monohydrate)
Drugs Prescribed More Frequently to Women
Pondimin Appetite Vavular heart disease
(fenfluramine suppressant
hydrochloride)
Redux Appetite Vavular heart disease
(dexyfenfluramine suppressant
hydrochloride)
Rezulin (troglitazone) Diabetic Liver failure
Lotronex Gastrointestinal Ischemic colitis (intestinal
(alosteron inflammation due to lack of
hydrochloride) blood flow)
Prescription Drugs Without Evidence of Greater Health Risks for Women
Raxar Antibiotic Torsades de Pointes
(grepafloxacin
hydrochloride)
Duract (bromfenac Analgesic and Liver failure
sodium) anesthetic
From U.S. Gen. Accounting Office, GAO-0 I -286R, Drug Safety: Most Drugs Withdrawn
in Recent Years Had Greater Health Risks for Women 2 (2001).
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